A Randomized, Double-Blind, Placebo-Controlled Study of Safety and Pharmacodynamic Effects of ABT-436 in Major Depressive Disorder Subjects.
Phase of Trial: Phase I
Latest Information Update: 23 Nov 2017
At a glance
- Drugs ABT 436 (Primary)
- Indications Major depressive disorder
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Sponsors Abbott Laboratories
- 22 Nov 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 01 Sep 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 08 Aug 2011 Planned End Date changed from 1 Oct 2011 to 1 Sep 2011 as reported by ClinicalTrials.gov.